Seeking Alpha

AstraZeneca (AZN) will pay Bristol-Myers Squibb (BMY) $135M to gain equal say in decision-making...

AstraZeneca (AZN) will pay Bristol-Myers Squibb (BMY) $135M to gain equal say in decision-making at Amylin Pharmaceuticals, which Bristol Myers has just bought for $7B. AstraZeneca is already paying $3.4B to Bristol-Myers to for a 50% share in Amylin's products, with the companies adding those products to an existing diabetes partnership. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector